Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1
In this cohort of 79 adult patients with NF1, <sup>18</sup>F-FDG PET/CT proved as a valuable complementary imaging modality to conventional imaging by enabling the detection of incidental malignant or potentially malignant tumors. Our results highlight <sup>18</sup>F-FDG PET/CT's beneficial impact on disease management by suggesting that the incorporation of <sup>18</sup>F-FDG PET/CT into screening protocols could improve early detection of NF1-related cancers in asymptomatic adults, potentially offering early treatment options to improve clinical outcomes.
Authors
- Mathieu Blais (ORCID: https://orcid.org/0009-0001-9102-378X)
- François-Alexandre Buteau
- Rahma Derbel
- Hélène T. Khuong (ORCID: https://orcid.org/0000-0001-5005-4144)
- Vincent Roy (ORCID: https://orcid.org/0000-0003-2583-6376)
- Manon Leclerc (ORCID: https://orcid.org/0009-0009-5958-6599)
- R Lamontagne (ORCID: https://orcid.org/0009-0002-5006-7054)
- Lina Djilani
- Mathilde Baril
- François Gros-Louis
- Nicolas Dupre
- Maria Gabriela Tanase
Institutions
- Centre hospitalier de l'Université Laval (CA)
- Université Laval (CA)
Publication Details
- Journal
- Neurology Genetics
- Published
- 2026-03-20
- DOI
- https://doi.org/10.1212/nxg.0000000000200361
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00